参考文献
［1］ 中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2020概要［J］.中国循环杂志,2021,36(6):521‑545. DOI: 10.3969/j.issn.1000‑3614.2021.06.001.
［2］ Zhao X, Kwan J, Yip K, et al. Targeting metabolic dysregulation for fibrosis therapy［J］. Nat Rev Drug Discov, 2020,19(1):57‑75. DOI: 10.1038/s41573‑019‑0040‑5.
［3］ Gyöngyösi M, Winkler J, Ramos I, et al. Myocardial fibrosis: biomedical research from bench to bedside［J］. Eur J Heart Fail, 2017,19(2):177‑191. DOI: 10.1002/ejhf.696.
［4］ Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure［J］. Nat Rev Cardiol, 2011,8(1):30‑41. DOI: 10.1038/nrcardio.2010.165.
［5］ González A, Schelbert EB, Díez J, et al. Myocardial interstitial fibrosis in heart failure: biological and translational perspectives［J］. J Am Coll Cardiol, 2018,71(15):1696‑1706. DOI: 10.1016/j.jacc.2018.02.021.
［6］ Liu M, López de Juan Abad B, Cheng K. Cardiac fibrosis: myofibroblast‑mediated pathological regulation and drug delivery strategies［J］. Adv Drug Deliv Rev, 2021,173:504‑519. DOI: 10.1016/j.addr.2021.03.021.
［7］ Wang X, Zhen L, Miao H, et al. Concomitant retrograde coronary venous infusion of basic fibroblast growth factor enhances engraftment and differentiation of bone marrow mesenchymal stem cells for cardiac repair after myocardial infarction［J］. Theranostics, 2015,5(9):995‑1006. DOI: 10.7150/thno.11607.
［8］ Li S, Ma Y, Yan Y, et al. Phosphodiesterase‑5a knock‑out suppresses inflammation by down‑regulating adhesion molecules in cardiac rupture following myocardial infarction［J］. J Cardiovasc Transl Res, 2021,14(5):816‑823. DOI: 10.1007/s12265‑021‑10102‑2.
［9］ Du Y, Wang X, Li L, et al. miRNA‑mediated suppression of a cardioprotective cardiokine as a novel mechanism exacerbating post‑MI remodeling by sleep breathing disorders［J］. Circ Res, 2020,126(2):212‑228. DOI: 10.1161/CIRCRESAHA.119.315067.
［10］ Jia L, Zhang W, Ma Y, et al. Haplodeficiency of ataxia telangiectasia mutated accelerates heart failure after myocardial infarction［J］. J Am Heart Assoc, 2017,6(7): e006349. DOI: 10.1161/JAHA.117.006349.
［11］ Friebel J, Weithauser A, Witkowski M, et al. Protease‑ activated receptor 2 deficiency mediates cardiac fibrosis and diastolic dysfunction［J］. Eur Heart J, 2019,40(40):3318‑3332. DOI: 10.1093/eurheartj/ehz117.
［12］ Sweeney M, Corden B, Cook SA. Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?［J］. EMBO Mol Med, 2020,12(10):e10865. DOI: 10.15252/emmm.201910865.
［13］ Huang X, Yan Y, Zheng W, et al. Secreted frizzled‑related protein 5 protects against cardiac rupture and improves cardiac function through inhibiting mitochondrial dysfunction［J］. Front Cardiovasc Med, 2021,8:682409. DOI: 10.3389/fcvm.2021.682409.
［14］ Díez J, Querejeta R, López B, et al. Losartan‑dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients［J］. Circulation, 2002,105(21):2512‑2517. DOI: 10.1161/01.cir.0000017264.66561.3d.
［15］ Brilla CG, Funck RC, Rupp H. Lisinopril‑mediated regression of myocardial fibrosis in patients with hypertensive heart disease［J］. Circulation, 2000,102(12):1388‑1393. DOI: 10.1161/01.cir.102.12.1388.
［16］ Zannad F, Radauceanu A. Effect of MR blockade on collagen formation and cardiovascular disease with a specific emphasis on heart failure［J］. Heart Fail Rev, 2005,10(1):71‑78. DOI: 10.1007/s10741‑005‑2351‑3.
［17］ Martin N, Manoharan K, Thomas J, et al. Beta‑blockers and inhibitors of the renin‑angiotensin aldosterone system for chronic heart failure with preserved ejection fraction［J］. Cochrane Database Syst Rev, 2018,6:CD012721. DOI: 10.1002/14651858.CD012721.pub2.
［18］ Solomon SD, McMurray J, Anand IS, et al. Angiotensin‑neprilysin inhibition in heart failure with preserved ejection fraction［J］. N Engl J Med, 2019,381(17):1609‑1620. DOI: 10.1056/NEJMoa1908655.
［19］ Heymans S, González A, Pizard A, et al. Searching for new mechanisms of myocardial fibrosis with diagnostic and/or therapeutic potential［J］. Eur J Heart Fail, 2015,17(8):764‑771. DOI: 10.1002/ejhf.312.
［20］ Gourdie RG, Dimmeler S, Kohl P. Novel therapeutic strategies targeting fibroblasts and fibrosis in heart disease［J］. Nat Rev Drug Discov, 2016,15(9):620‑638. DOI: 10.1038/nrd.2016.89.
［21］ Kotlarz D, Marquardt B, Barøy T, et al. Human TGF‑β1 deficiency causes severe inflammatory bowel disease and encephalopathy［J］. Nat Genet, 2018,50(3):344‑348. DOI: 10.1038/s41588‑018‑0063‑6.
［22］ Mitra MS, Lancaster K, Adedeji AO, et al. A Potent Pan‑TGFβ Neutralizing monoclonal antibody elicits cardiovascular toxicity in mice and cynomolgus monkeys［J］. Toxicol Sci, 2020,175(1):24‑34. DOI: 10.1093/toxsci/kfaa024.
［23］ Umbarkar P, Singh AP, Gupte M, et al. Cardiomyocyte SMAD4‑dependent TGF‑β signaling is essential to maintain adult heart homeostasis［J］. JACC Basic Transl Sci, 2019,4(1):41‑53. DOI: 10.1016/j.jacbts.2018.10.003.
［24］ Lacouture ME, Morris JC, Lawrence DP, et al. Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008)［J］. Cancer Immunol Immunother, 2015,64(4):437‑446. DOI: 10.1007/s00262‑015‑1653‑0.
［25］ Al‑U′datt D, Allen BG, Nattel S. Role of the lysyl oxidase enzyme family in cardiac function and disease［J］. Cardiovasc Res, 2019,115(13):1820‑1837. DOI: 10.1093/cvr/cvz176.
［26］ Hermida N, López B, González A, et al. A synthetic peptide from transforming growth factor‑beta1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats［J］. Cardiovasc Res, 2009,81(3):601‑609. DOI: 10.1093/cvr/cvn315.
［27］ Yang J, Savvatis K, Kang JS, et al. Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment［J］. Nat Commun, 2016,7:13710. DOI: 10.1038/ncomms13710.
［28］ Neff LS, Bradshaw AD. Cross your heart? Collagen cross‑links in cardiac health and disease［J］. Cell Signal, 2021,79:109889. DOI: 10.1016/j.cellsig.2020.109889.
［29］ Shinde AV, Dobaczewski M, de Haan JJ, et al. Tissue transglutaminase induction in the pressure‑overloaded myocardium regulates matrix remodelling［J］. Cardiovasc Res, 2017,113(8):892‑905. DOI: 10.1093/cvr/cvx053.
［30］ Shinde AV, Su Y, Palanski BA, et al. Pharmacologic inhibition of the enzymatic effects of tissue transglutaminase reduces cardiac fibrosis and attenuates cardiomyocyte hypertrophy following pressure overload［J］. J Mol Cell Cardiol, 2018,117:36‑48. DOI: 10.1016/j.yjmcc.2018.02.016.
［31］ Russo I, Frangogiannis NG. Diabetes‑associated cardiac fibrosis: cellular effectors, molecular mechanisms and therapeutic opportunities［J］. J Mol Cell Cardiol, 2016,90:84‑93. DOI: 10.1016/j.yjmcc.2015.12.011.
［32］ Watson AM, Gray SP, Jiaze L, et al. Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing RAGE activation in diabetic apolipoprotein E knockout mice［J］. Diabetes, 2012,61(8):2105‑2113. DOI: 10.2337/db11‑1546.
［33］ Brunt VE, Casso AG, Gioscia‑Ryan RA, et al. Gut microbiome‑derived metabolite trimethylamine n‑oxide induces aortic stiffening and increases systolic blood pressure with aging in mice and humans［J］. Hypertension, 2021,78(2):499‑511. DOI: 10.1161/HYPERTENSIONAHA.120.16895.
［34］ Candido R, Forbes JM, Thomas MC, et al. A breaker of advanced glycation end products attenuates diabetes‑induced myocardial structural changes［J］. Circ Res, 2003,92(7):785‑792. DOI: 10.1161/01.RES.0000065620.39919.20.
［35］ Christensen G, Herum KM, Lunde IG. Sweet, yet underappreciated: proteoglycans and extracellular matrix remodeling in heart disease［J］. Matrix Biol, 2019,75‑76∶286‑299. DOI: 10.1016/j.matbio.2018.01.001.
［36］ Adam O, Zimmer C, Hanke N, et al. Inhibition of aldosterone synthase (CYP11B2) by torasemide prevents atrial fibrosis and atrial fibrillation in mice［J］. J Mol Cell Cardiol, 2015,85:140‑150. DOI: 10.1016/j.yjmcc.2015.05.019.
［37］ Hermida N, Markl A, Hamelet J, et al. HMGCoA reductase inhibition reverses myocardial fibrosis and diastolic dysfunction through AMP‑activated protein kinase activation in a mouse model of metabolic syndrome［J］. Cardiovasc Res, 2013,99(1):44‑54. DOI: 10.1093/cvr/cvt070.
［38］ Martínez‑González J, Varona S, Cañes L, et al. Emerging roles of lysyl oxidases in the cardiovascular system: new concepts and therapeutic challenges［J］. Biomolecules, 2019,9(10): 610. DOI: 10.3390/biom9100610.
［39］ Fickert P. Is this the last requiem for simtuzumab?［J］. Hepatology, 2019,69(2):476‑479. DOI: 10.1002/hep.30309.
［40］ Rowbottom MW, Bain G, Calderon I, et al. Identification of 4‑(aminomethyl)‑6‑(trifluoromethyl)‑2‑(phenoxy) pyridine derivatives as potent, selective, and orally efficacious inhibitors of the copper‑dependent amine oxidase, lysyl oxidase‑like 2 (LOXL2)［J］. J Med Chem, 2017,60(10):4403‑4423. DOI: 10.1021/acs.jmedchem.7b00345.
［41］ Tatsukawa H, Hitomi K. Role of transglutaminase 2 in cell death, survival, and fibrosis［J］. Cells, 2021,10(7)：1842. DOI: 10.3390/cells10071842.
